Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non‐small cell lung cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|15|2289-2298

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.15, 2014-08, pp. : 2289-2298

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4325-4332

John Wiley & Sons Inc

Access to resources Recommend Favorite

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer

By  

Oncology, Vol. 91, Iss. 1, 2016-07 ,pp. : 26-34

Karger

Access to resources Recommend Favorite

Challenges in the Management of EGFR-Mutated Non-Small Cell Lung Cancer Patients with Acquired Resistance to Tyrosine Kinase Inhibitors

By  

Oncology, Vol. 87, Iss. 2, 2014-07 ,pp. : 83-94

Karger

Access to resources Recommend Favorite

Epidermal Growth Factor Receptor Inhibition and Non-Small Cell Lung cancer

By von Eyben Finn  

Critical Reviews in Clinical Laboratory Sciences, Vol. 43, Iss. 4, 2006-08 ,pp. : 291-323

Informa Healthcare

Access to resources Recommend Favorite

Targeting the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 33, Iss. 12, 2010-11 ,pp. : 704-709

Karger

Access to resources Recommend Favorite